Neurocrine is paying $145,000 per patient for a drug that works
$2.9B for Soleno means $100K+ per patient annually, for a drug with no competition and 20,000 US patients. The access question is who absorbs that cost — and what happens when they cannot.
image from grok
Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion to gain Vykat XR, the sole approved treatment for hyperphagia in Prader-Willi syndrome, priced at approximately $145,000 annually per patient. The deal values the drug at a premium justified by a defined US patient population of ~20,000, no competitive alternatives, and BMO's projection of $450M in 2026 sales growing to $2B globally by the mid-2030s. The acquisition exemplifies how rare disease pricing leverage—small populations, lifelong treatment courses, and unmet medical need—creates commercially attractive but ethically fraught valuations that depend on payor absorption rather than market competition.
- •Rare disease pricing leverage is structural: with no alternatives and lifelong treatment requirements, manufacturers can command six-figure annual costs regardless of competition, as demonstrated by Vykat XR's $145K+ per-patient pricing.
- •The $2.9B acquisition price implies payer acceptance of current pricing, validated by $190M in nine-month sales post-approval and analyst projections of near-term $450M annual revenue.
- •Prader-Willi syndrome's ~20,000 US diagnosed patients represent a contained commercial universe where market penetration math is predictable, enabling precise return-on-investment modeling for deal valuations.
